Moonlake Immunotherapeutics (MLTX)
NASDAQ:MLTX
Want to see MLTX full AI Analyst Report?
MLTX Stock Chart & Stats
$18.34
-$0.83(-1.65%)
At close: 4:00 PM EST
$18.34
-$0.83(-1.65%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume45.38K
Average Volume (3M)904.80K
Market Cap
$1.41B
Enterprise Value$1.21B
Total Cash (Recent Filing)$357.92M
Total Debt (Recent Filing)$100.80M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 12, 2026EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.88
Shares Outstanding73,615,395
10 Day Avg. Volume791,151
30 Day Avg. Volume904,800
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-519.67
Enterprise Value/Ebitda-4.94
Forecast
1Y Price Target
$32.67Price Target Upside78.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress Toward BLAA favorable final pre-BLA meeting with the FDA and an agreed submission plan materially de-risks regulatory execution. This clears a defined path to a Biologics License Application and potential U.S. launch, converting MoonLake from purely development-stage to near-commercial conditional on approval, improving strategic optionality.
Secured Long-term Manufacturing CapacityA confirmed commercial manufacturing partner with reserved capacity materially reduces execution risk for a first launch. Long-term capacity commitments help ensure product supply continuity, supporting commercialization planning, labeling and launch timing—critical structural capabilities for a biologics developer moving to market.
Material Liquidity And Committed FinancingSubstantial cash on hand plus a committed debt facility provides a durable runway to complete Phase 3 readouts and submit the BLA. This financing buffer reduces near-term dilution risk and supports continued R&D and regulatory activity through key upcoming milestones if managed alongside operating burn.
Bears Say
No Revenue, Persistent Large LossesMoonLake remains pre-commercial with no product revenue and multi-year widening losses, implying continued reliance on external financing. Persistent operating deficits translate into sustained cash burn and elevated execution risk until commercial sales materialize, pressuring long-term funding needs and strategic flexibility.
Rising Leverage And Higher Debt RelianceRapid increases in debt materially raise financial risk for a pre-revenue biotech. Higher leverage reduces balance-sheet flexibility, increases interest and covenant sensitivity, and magnifies refinancing or market-pressure risks if development timelines slip or cash burn persists, constraining strategic choices.
Manufacturing Minimums Create Fixed-cost ExposureWhile capacity is secured, contractual minimums and potential compensation payments create structural fixed-cost obligations. If regulatory delays or weaker-than-expected demand occur, these commitments could increase per-unit costs, strain margins post-launch, and amplify funding needs or pricing pressure over the medium term.
MoonLake Immunotherapeutics News
MLTX FAQ
What was Moonlake Immunotherapeutics’s price range in the past 12 months?
Moonlake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is Moonlake Immunotherapeutics’s market cap?
Moonlake Immunotherapeutics’s market cap is $1.41B.
When is Moonlake Immunotherapeutics’s upcoming earnings report date?
Moonlake Immunotherapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 52 days.
How were Moonlake Immunotherapeutics’s earnings last quarter?
Moonlake Immunotherapeutics released its earnings results on May 10, 2026. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.892 by -$0.088.
Is Moonlake Immunotherapeutics overvalued?
According to Wall Street analysts Moonlake Immunotherapeutics’s price is currently Undervalued.
Does Moonlake Immunotherapeutics pay dividends?
Moonlake Immunotherapeutics does not currently pay dividends.
What is Moonlake Immunotherapeutics’s EPS estimate?
Moonlake Immunotherapeutics’s EPS estimate is -0.93.
How many shares outstanding does Moonlake Immunotherapeutics have?
Moonlake Immunotherapeutics has 73,615,395 shares outstanding.
What happened to Moonlake Immunotherapeutics’s price movement after its last earnings report?
Moonlake Immunotherapeutics reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.892. Following the earnings report the stock price went up 4.541%.
Which hedge fund is a major shareholder of Moonlake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.67 (78.12% Upside)
$32.67 (78.12% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 52.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-55.83%
12-Months-Change
Fundamentals
Return on Equity
-85.61%
Trailing 12-Months
Asset Growth
-21.69%
Trailing 12-Months
Company Description
Moonlake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$32.67
▲(78.12% Upside)
Technical Analysis
Ownership Overview
13.55% Insiders
2.18% Mutual Funds
54.88% Other Institutional Investors
28.67% Public Companies and
Individual Investors